Obesity treatment Poznań

Obesity is a chronic disease with multiple causes, classified as E66 in ICD-10. After weight loss, changes in appetite and energy expenditure can make maintaining the result harder and, in some people, lead to regaining the lost weight. That is why at the Nasz Gabinet clinic in Poznań we plan obesity treatment for adults over the long term and regularly review its effectiveness and tolerability.

What makes a person develop obesity?

Obesity develops when, over months and years, a person takes in more energy from food than they use, and the accumulated fat tissue begins to harm health. The surplus energy goes into fat cells. At first each of these cells stores more fat and grows larger, and with further weight gain the body produces new fat cells. Fat tissue is also a hormone-producing organ: it releases leptin and pro-inflammatory substances into the blood, and these substances reduce the sensitivity of tissues to insulin. Visceral fat, which collects in the abdomen around the internal organs, does the most harm.

Genes have a strong influence on who develops the disease. Twin studies show that genes account for 40 to 70 percent of the differences in body weight between people, and obesity often runs in families. A person with this tendency gains weight especially when high-calorie food is available every day and most of the day is spent sitting, at work and while travelling. Pregnancy, menopause and the period after quitting smoking are also times of faster weight gain. Some diseases and medicines can also increase body weight, so before the first prescription we check test results and the full list of medicines the patient takes.

Stress, low mood and poor sleep can change appetite and eating habits. Some patients link the start of their weight gain to an episode of depression, starting a psychiatric medicine, losing a job or shift work. We take this history into account in treatment; emotional eating does not in itself mean addiction. Obesity medicines can make appetite easier to control, but they do not replace psychological help or treatment for an eating disorder. For depression or weight gain on psychiatric medication, we agree the treatment plan with the treating psychiatrist.

We start by calculating body mass index (BMI): weight in kilograms divided by height in metres squared. At 178 cm and 98 kg, BMI is about 31, indicating class I obesity. WHO thresholds are 25 for overweight, 30 for class I obesity, 35 for class II and 40 for class III. We also measure waist circumference. IDF thresholds for abdominal obesity in people of European ancestry are 80 cm for women and 94 cm for men. This helps assess metabolic risk but does not by itself establish eligibility for medication.

We ask about weight at age 20, when weight gain began and changes after psychiatric treatment, depression, pregnancy, stopping smoking or moving to sedentary work. Gaining 10 kg in six months after starting a medicine calls for a different assessment of causes from gradual gain over 20 years. We also assess symptoms of depression and eating disorders.

When should you book a consultation, and when can medication be considered?

You can seek a consultation for overweight or rapid weight gain. Eligibility for medication is assessed separately: for the incretin medicines discussed here and Mysimba, this generally means BMI of at least 30, or at least 27 with an appropriate related condition, such as hypertension, abnormal blood lipids, sleep apnoea or impaired glucose regulation. Xenical has an overweight threshold of 28 with risk factors. The doctor checks the individual product's criteria, contraindications and previous treatment. Gaining 15 kg, having a large waist or not achieving the hoped-for result with diet does not replace these criteria.

In Poland, an obesitologist is a doctor working in obesity care, not a separate formally recognised medical specialty. The Polish Association for the Study of Obesity runs a certification programme for doctors.

Our obesity treatment programme lasts 6 months, takes place online and costs PLN 1,799. The medicine is not included in this amount, because you buy it at a pharmacy with an e-prescription. Before starting, you have blood tests done and measure your weight, waist circumference and blood pressure at home. The doctor decides on admission to the programme after assessing your medical history and results. The programme includes two 30-minute doctor consultations, two 40-50-minute online consultations with a psychologist and five medical reviews of app data without a call. You book the video consultations in the Nasz Gabinet app, and the dates are counted from the initial consultation.

The price also includes an AI assistant and monitoring of body weight and treatment progress.

Between consultations you record weekly weight measurements and monthly body measurements in the app. After the injection, you take a photo of the pen with the used needle, which the medical team looks at. The doctor looks through these results before every check-up. Effectiveness is assessed according to the medicine's specific requirements. Mood monitoring is particularly important with depression or psychiatric medication; Mysimba requires close observation, especially at the start and after dose changes.

The end of the programme is not an automatic point for stopping the medicine. The Polish Society for the Treatment of Obesity (PTLO) recommends treating obesity for a year or longer, which is why after the programme we offer a continuation package for 3 months for PLN 350. In the package the doctor reviews the results from the app every month and issues an e-prescription, without video consultations.

What does our obesity treatment programme not include?

• We do not independently stop psychiatric medicines or change their doses. Changes to olanzapine, mirtazapine or another psychiatric medicine are for the treating psychiatrist to decide; we share relevant information about treatment.
• We do not start obesity treatment during acute alcohol or benzodiazepine withdrawal. Health must first stabilise. Mysimba is contraindicated during acute withdrawal; other medicines need a separate assessment.
• This programme is for adults aged 18 and over. Children and adolescents need paediatric care; local options are described below and in the FAQ.

Before a first prescription, the doctor reviews tests such as fasting glucose, glycated haemoglobin (HbA1c), lipids, ALT and AST, creatinine with eGFR, TSH, uric acid and a blood count. The selection is tailored to your circumstances. HbA1c helps assess average glucose over about 2 to 3 months and is interpreted alongside glucose, symptoms and health status. eGFR assesses kidney function. TSH is an initial thyroid assessment, supplemented by free T4 when indicated. ALT and AST help assess the liver but do not alone diagnose fatty liver or its cause. A lipid profile measures cholesterol and triglycerides.

Have your previous results ready. Whether tests need repeating depends on your health, treatment changes and earlier measurements, not just the date. Monitoring glucose and lipids matters with clozapine and olanzapine even independently of weight changes. Missing tests can be performed at a laboratory of your choice.

A list of all medicines, over-the-counter products and supplements is equally important. Have packages or photographs ready and record doses, how long you have taken them and the prescribing doctor. We check specific interactions, particularly with naltrexone/bupropion, and also with orlistat.

When is coordination with a psychiatrist or endocrinologist needed?

Suspected hypothyroidism calls for further assessment and a treatment plan; this need not delay all obesity care. A rounded face, broad purple stretch marks or unusual hypertension may warrant testing for Cushing's syndrome but do not establish the diagnosis. Glucocorticoids, insulin, sulfonylureas and some antiepileptic and psychiatric medicines can also contribute to weight gain. We discuss possible alternatives with the treating specialist if the underlying condition permits. The timing of obesity treatment is individual.

A meta-analysis of 15 observational studies found a two-way association: people with obesity more often subsequently developed depression, and people with depression more often developed obesity. Depression can contribute to weight gain through appetite, sleep and activity changes, but not everyone gains weight. We ask about mood at the initial consultation and at check-ups. Screening tools such as the Beck Depression Inventory can help when depression is suspected; diagnosis requires clinical assessment. Obesity and depression can be treated alongside one another.

Some psychiatric medicines increase appetite and weight. The table draws on a 2020 meta-analysis of 100 trials involving 25,952 people with schizophrenia and a 2010 review of 116 antidepressant studies. It describes average associations, not a prediction for an individual.

What we do when a patient gains weight on psychiatric medication and cannot stop it

If olanzapine or clozapine controls the psychiatric illness, maintaining it may be the priority. We coordinate the plan with the psychiatrist and assess obesity medication eligibility separately. In a 2017 trial, 103 people with schizophrenia taking clozapine or olanzapine, with overweight or obesity and prediabetes, received liraglutide 1.8 mg daily or placebo for 16 weeks. The between-group weight-change difference was 5.3 kg in favour of liraglutide; normal glucose tolerance was achieved by 63.8% versus 16%. Psychotic symptoms did not worsen in this trial. However, this was not the Saxenda 3 mg regimen: Saxenda's product information does not recommend its use for obesity secondary to weight-increasing medicines or eating disorders. The trial does not establish automatic eligibility for Saxenda.

Newer semaglutide trials are also available. In HISTORI, published in 2025, 154 people with schizophrenia, prediabetes and BMI of at least 27 taking second-generation antipsychotics received semaglutide up to 1 mg weekly or placebo for 30 weeks. The between-group weight-change difference was 9.21 kg in favour of semaglutide. This finding applies to that population, dose and duration; it cannot automatically be extended to tirzepatide.

Metformin is another option a doctor may consider. A meta-analysis of 20 trials with 1,070 participants found a mean weight difference of about 3.3 kg in its favour versus placebo for antipsychotic-associated weight gain. This is an off-label use. The doctor assesses the rationale, kidney function and tolerability and coordinates with the treating specialist.

How is binge-eating disorder treated?

Episodes involve eating a large amount in a short time, a sense of losing control and marked distress. At least one episode a week for 3 months is one diagnostic criterion, but it is not sufficient on its own. Other features include the absence of regular compensatory behaviours such as induced vomiting or fasting. A US population survey of 9,282 people conducted from 2001 to 2003, using the diagnostic criteria of that time, found lifetime prevalence of 3.5% in women and 2% in men. These are not Poznań population figures.

Obesity medicines may help control appetite but do not replace eating-disorder treatment. For adults, NICE recommends cognitive behavioural guided self-help with professional support. If unsuitable or ineffective after 4 weeks, group eating-disorder-focused CBT is an option, with individual therapy when a group is unavailable or declined. Medical, dietary and psychotherapeutic care is arranged according to needs and availability. A history of anorexia or bulimia is a contraindication to Mysimba.

Can obesity medicines worsen mood or cause suicidal thoughts?

In April 2024, the EMA concluded that available evidence did not support a causal link between suicidal thoughts or self-harm and semaglutide, liraglutide, dulaglutide, exenatide or lixisenatide. That assessment did not include tirzepatide and does not guarantee that mood can never worsen.

Mysimba contains the antidepressant bupropion and requires monitoring, especially at the start and after dose changes. The antidepressant warning includes the risk of suicidal behaviour in people under 25. Depression alone is not an automatic contraindication, but the condition, medicines and interactions need assessment. Contraindications include a history of bipolar disorder or seizures, acute alcohol or benzodiazepine withdrawal and taking another bupropion or naltrexone product. MAO inhibitors and serotonergic medicines must also be checked. New agitation, insomnia or worsening mood needs prompt medical contact. An immediate risk of suicide requires urgent medical help.

GLP-1 and GIP are gut hormones released after meals that help regulate blood glucose. GLP-1 also helps regulate appetite. Semaglutide and liraglutide activate the GLP-1 receptor; tirzepatide activates both GIP and GLP-1 receptors. These medicines can increase fullness, reduce appetite and slow stomach emptying. We use them after checking eligibility and safety, alongside changes in eating and activity. A lack of success with diet alone does not replace a product's eligibility criteria.

Injectable semaglutide and tirzepatide are given once weekly, and liraglutide daily. Dose escalation differs: liraglutide is usually increased at intervals of at least a week, rather than every 4 weeks as in the initial semaglutide schedule. Dosing is described below.

Trial results and assessment of treatment effectiveness

In STEP 1, participants taking semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks, compared with 2.4% on placebo. In SURMOUNT-1, tirzepatide 15 mg produced a 20.9% loss at 72 weeks, versus 3.1% on placebo. In SCALE, liraglutide 3 mg reduced weight by 8.4 kg at 56 weeks, compared with 2.8 kg on placebo. These were separate trials in people without type 2 diabetes, with dietary and activity support; they are not a direct comparison of the medicines.

For a starting weight of 98 kg, 14.9% corresponds to about 15 kg and 20.9% to about 20 kg. This illustrates the percentages rather than predicting your result. We assess health benefits, tolerability and outcomes under the rules for each medicine. We do not automatically switch semaglutide to tirzepatide at one arbitrary time point. Weight stabilises at different times; maintaining a lower weight can be an important treatment benefit.

When can stopping medication be considered?

In the STEP 1 extension, after semaglutide and lifestyle support ended, participants regained on average about two-thirds of their lost weight within a year. Some metabolic benefits also diminished. The study did not test whether gradually lowering the dose prevents weight regain.

Continuing or stopping is an individual decision based on effectiveness, side effects, preferences and a follow-up plan. Stable weight or a year of therapy does not automatically mean stopping. If psychiatric medication must continue, we regularly review benefits and risks rather than predetermining obesity treatment for its entire duration.

Wegovy, Mounjaro, Saxenda, Mysimba and Xenical are the obesity treatments discussed here. Choice depends on the individual product's indications, health, other medicines, tolerability and costs. Off-label use requires a separate medical decision and differs from use in accordance with the summary of product characteristics (SmPC).

Ozempic and Wegovy: how do their indications and doses differ?

Ozempic and Rybelsus contain semaglutide and are authorised for type 2 diabetes; Wegovy is for weight management. Saxenda is liraglutide with a target dose of 3 mg daily, while Victoza is liraglutide up to 1.8 mg daily for type 2 diabetes. Mounjaro is indicated both for type 2 diabetes and weight management. For obesity treatment, we choose a product with the relevant indication.

Wegovy injections start at 0.25 mg weekly, usually increasing every 4 weeks to 2.4 mg. The current SmPC also allows 7.2 mg in adults with initial BMI of at least 30 if additional benefit is needed after at least 4 weeks on 2.4 mg. EU authorisation of this dose and an oral formulation does not mean every variant is available in Polish pharmacies; availability is checked separately. Mounjaro starts at 2.5 mg weekly and rises to 5 mg after 4 weeks. Further 2.5 mg increases are made only if needed, after at least 4 weeks at the current dose. Maintenance doses are 5, 10 or 15 mg. Saxenda starts at 0.6 mg daily and increases by 0.6 mg at intervals of at least a week to 3 mg. The doctor sets the schedule according to tolerability and the SmPC.

Estimating the cost of obesity medicines

Patients pay the full pharmacy price for these products when treating obesity. Cost depends on the product, dose, number of packs and pharmacy. A pack price does not always cover 30 days; weekly treatments often cover 4 weeks. Ask the pharmacy to price the quantity needed for your prescribed schedule. Wegovy 7.2 mg needs a separate estimate rather than extrapolating prices for doses up to 2.4 mg. Prices of alternative liraglutide products are not Saxenda brand prices. On top of the cost of the medicine comes the price of our programme, PLN 1,799 for 6 months.

When do we choose Mysimba or Xenical instead of an injection?

Mysimba combines naltrexone and bupropion and affects appetite regulation and the reward system. In COR-I, mean weight loss at 56 weeks was 6.1%, versus 1.3% on placebo. Treatment is stopped if loss is below 5% after 16 weeks from starting. Ongoing effectiveness and safety, including cardiovascular risk, are assessed annually; after one year, treatment should stop if a loss of at least 5% has not been maintained. Contraindications and interactions are particularly important with psychiatric treatment.

Xenical is orlistat in 120 mg hard capsules. It inhibits digestive lipases and reduces absorption of about one-third of dietary fat rather than binding fat. Trials showed about 2 to 3 kg greater weight loss than placebo after a year. Oily stools and urgency may occur, especially after fatty meals. Treatment stops if weight loss is below 5% after 12 weeks. For Saxenda, the 5% threshold is assessed after 12 weeks at 3 mg daily.

Orlistat acts in the gut but may reduce the effectiveness of some antidepressants, antipsychotics, lithium and benzodiazepines; antiepileptic medicines also need review. It is not automatically safer during psychiatric treatment. Mysimba or Xenical may be considered after reviewing indications, tolerability, interactions and preferences.

Nausea, vomiting, diarrhoea and constipation are common with incretin medicines, particularly during dose escalation. In STEP 1, gastrointestinal symptoms led 4.5% of semaglutide participants to stop treatment. Smaller meals, less fatty food and hydration suited to your health may help. The doctor decides further dosing. Inability to keep fluids down, reduced urination or increasing weakness requires urgent assessment; do not wait for a full day to pass.

Vomiting and diarrhoea can affect taking and absorbing oral medicines. Dehydration increases the risk of lithium toxicity. Marked tremor, unsteadiness or confusion in someone taking lithium needs urgent care; the doctor plans lithium-level and kidney-function monitoring.

When is a medicine contraindicated, and when is caution needed?

• Pregnancy: semaglutide, liraglutide and tirzepatide should not be used. Stop semaglutide at least 2 months and tirzepatide at least one month before a planned pregnancy. Wegovy and Saxenda should not be used while breastfeeding; a doctor may consider Mounjaro after an individual assessment.
• Previous pancreatitis requires caution and individual assessment rather than a blanket ban. If acute pancreatitis is confirmed during treatment, that medicine must not be restarted. Tell the doctor about familial medullary thyroid carcinoma; it is not a shared formal contraindication in the EU SmPCs.
• Wegovy and Saxenda are not recommended in severe renal or hepatic impairment. Mounjaro does not require dose adjustment for these conditions, but caution is needed in severe impairment. Wegovy and Saxenda are also not recommended in NYHA class IV heart failure.
• Saxenda is not recommended from age 75. Experience with Wegovy and Mounjaro from age 85 is limited. The Saxenda restriction for obesity secondary to medicines or eating disorders is discussed in the psychiatric-treatment section.
• The EU Mounjaro SmPC does not require an oral contraceptive dose adjustment. An additional barrier method for 4 weeks after starting and after each dose increase is a precautionary recommendation, not a requirement of that SmPC. Follow the contraceptive's instructions if vomiting or diarrhoea occurs.
• A doctor may reduce insulin or sulfonylurea doses if hypoglycaemia risk warrants it; this is not automatic for everyone.
• Mysimba is contraindicated in conditions including a history of seizures, uncontrolled hypertension, bipolar disorder, past anorexia or bulimia, acute alcohol or benzodiazepine withdrawal, opioid use, severe hepatic impairment and end-stage renal failure. In moderate or severe renal impairment, the maximum dose is 2 tablets daily. Bupropion and naltrexone must not be duplicated. Trials reported seizures in 2 of 3,239 treated participants and none on placebo.

Symptoms requiring urgent medical care

Severe, persistent upper abdominal pain, especially radiating to the back, may indicate pancreatitis: seek urgent assessment and do not take the next dose until a doctor decides. Pain under the right ribs with fever or jaundice may signal complications of biliary disease. Gallstones were reported in 1.6% of semaglutide-treated participants in trials. Sudden deterioration or loss of vision needs urgent ophthalmic assessment; in 2025, the EMA classified NAION, an ischaemic optic nerve injury, as a very rare semaglutide adverse effect.

For suspected hypoglycaemia, someone conscious and able to swallow safely should take fast-acting carbohydrate according to their agreed plan and check glucose. Loss of consciousness or inability to swallow requires immediate medical help; give nothing by mouth to someone who is unconscious or unable to swallow. New psychiatric symptoms require prompt medical contact; an immediate risk of suicide requires urgent medical help.

Why should medicines be bought from a licensed pharmacy?

A licensed pharmacy uses a controlled supply chain and medicine authentication systems. Poland's Chief Pharmaceutical Inspectorate warned about counterfeit Ozempic. In October 2023, Austria reported hospitalisations after counterfeit pens containing insulin instead of semaglutide. Buying through an advertisement lacks pharmacy supply safeguards. Products sold as research peptides are not approved human medicines and do not offer the quality and sterility assurance required for medicines. Buy prescribed treatment from a licensed pharmacy and agree dosing with your doctor.

With a smaller appetite, meals need to provide nutrients and help preserve muscle. A protein target of around 1-1.5 g per kilogram of reference body weight daily can be considered, adjusted individually, including for kidney disease. Spread it across 3-4 meals: 85 g of cooked chicken breast provides about 28 g of protein and 100 g of semi-fat quark about 18 g. Yoghurt varies by product, so check the label. An energy deficit, often around 500-750 kcal daily, is tailored to need; overly restrictive eating can contribute to deficiencies and weakness.

With psychiatric medicines, regular meals and a planned evening meal can help, especially with increased evening appetite. Sugar-free drinks can help with a dry mouth. Activity supports muscle, fitness and metabolic health and increases energy expenditure. General adult recommendations include 150-300 minutes of moderate activity weekly and muscle-strengthening exercise on at least 2 days, allowing recovery. For knee pain, choose tolerable activity such as swimming or resistance exercise.

How does stress eating differ from a binge-eating episode?

Eating after an argument, snacking in front of a screen or eating after a night shift should be considered alongside emotions, sleep and earlier meals. Medicines can help appetite control but do not replace addressing these difficulties. Identifying triggers and planning a response can help: a short walk, another way to relieve tension or an earlier planned meal.

Emotional eating and binge-eating disorder cannot be distinguished by one question about control alone. Repeated loss of control, rapid eating in secret and marked distress need specialist assessment. A meal-plan change alone does not replace eating-disorder treatment. The programme includes two online consultations with a psychologist, after months 1 and 3. Dietitian and psychodietitian consultations are not included; any further treatment depends on the assessment.

Alcohol provides 7 kcal per gram. Two large beers may provide around 450 kcal and a bottle of wine around 600 kcal, depending on volume and composition. These calories can substantially reduce a planned energy deficit. Alcohol can also make eating harder to control and worsen gastrointestinal symptoms. With insulin or sulfonylureas, it increases hypoglycaemia risk, whose symptoms may be mistaken for intoxication.

During dose escalation, we recommend avoiding alcohol as a precaution. Further advice depends on health, medicines and drinking patterns; one drink daily is not a universally safe dose. Alcohol should be minimised or avoided with Mysimba. Acute alcohol withdrawal is a contraindication. Naltrexone is also used for alcohol dependence, but Mysimba does not replace that treatment and must not be combined with another naltrexone product.

In a phase 2 trial published in JAMA Psychiatry in 2025, 48 people with alcohol use disorder received semaglutide or placebo for 9 weeks. Semaglutide was associated with lower craving and less consumption on drinking days. These are preliminary findings; semaglutide is not authorised for treating alcohol dependence. For difficulty controlling drinking, we offer alcohol dependence treatment in Poznań, and for other substances, addiction therapy. Obesity treatment timing is agreed after acute withdrawal resolves and health stabilises, with the treating doctor.

We run the programme entirely online. You connect with the doctor and the psychologist by video in the Nasz Gabinet app, so you do not travel to Poznań for appointments. Before the initial consultation, you have blood tests done at a laboratory of your choice, list the medicines you take and measure your weight, waist circumference and blood pressure at home. The e-prescription code arrives by text message.

At the five monthly reviews, the doctor assesses the measurements and other information in the app, without a call. Further dosing and the next e-prescription follow medical assessment. If video calls are difficult, someone close to you can help with connecting. If your health suddenly gets worse, do not wait until a scheduled check-up to seek medical help.

NFZ-funded care includes primary care consultations, medically indicated tests within covered benefits, specialist care and bariatric surgery after assessment. The NFZ directory lists metabolic clinics in Poznań, Konin, Leszno, Jarocin, Koło and Kępno. Entries can represent different services at the same facility; check accepted ages, referral requirements and current appointment availability before booking. A metabolic-clinic referral does not have to come only from a GP.

Dietary consultations in coordinated primary care depend on eligibility for a specific pathway, for example for diabetes, hypertension or thyroid disease; obesity alone does not automatically give access to the whole package. An outpatient NFZ psychiatrist does not require a referral. Sharing records and current medication lists helps specialists coordinate care.

Wegovy, Mounjaro, Saxenda, Mysimba and Xenical are paid for in full for obesity treatment. Ozempic reimbursement applies to specified type 2 diabetes indications and current reimbursement-list criteria, not all semaglutide therapy. Our online programme is private and costs PLN 1,799 for 6 months. Medicines are purchased separately from a pharmacy.

Bariatric consultation is considered, among other situations, at BMI of at least 40 or at least 35 with obesity-related conditions; these are the traditional eligibility thresholds. Newer clinical recommendations also include BMI of at least 35 without complications and selected cases at BMI 30-34.9, for example inadequately controlled type 2 diabetes. The centre assesses clinical indications, funding conditions and preparation; not every consultation requires first trying every medicine.

Psychological and, where needed, psychiatric assessment helps prepare for changes after surgery. Unstable mental health or active addiction may need treatment beforehand. Depression or a binge-eating disorder diagnosis alone does not automatically exclude surgery; the bariatric team agrees the plan.

The Association of Polish Surgeons lists two bariatric centres in Poznań. Confirm current eligibility and NFZ availability with the centre. The KOS-BAR pilot ended on 30 June 2026; bariatric operations remain available through standard NFZ arrangements.

Before surgery, we gather treatment records and tailor tests and dietary preparation to the centre's advice. Reducing liver volume can facilitate surgery. Afterwards, eating capacity and, depending on the operation, nutrient and medicine absorption can change. The psychiatrist should know about planned surgery to review oral medication. Lifelong follow-up, supplementation and tests tailored to the operation and results are needed. Medication may also be considered for weight regain, regardless of how long it has been since surgery.

We run the programme online, so it is also open to patients from Gniezno, Września, Środa Wielkopolska, Śrem, Kościan, Leszno, Konin, Kalisz, Ostrów Wielkopolski, Piła and Szamotuły, and from around Poznań: Swarzędz, Luboń, Komorniki, Tarnowo Podgórne, Suchy Las and Kórnik.

You have blood tests done locally and have your consultations by video. If your psychiatric care is outside Poznań, provide your current medication list and records. Relevant findings about weight change and treatment are shared with the treating specialist.

Obesity data for Wielkopolska require cautious interpretation. A Supreme Audit Office report covering 2020-2022 found weight-measurement data reported for 1.1-19.3% of patients, depending on region and year. Wielkopolska had a low proportion of recorded obesity diagnoses and the highest absolute number of deaths with obesity as the immediate cause in 2020: 82. This is not a current obesity-prevalence estimate or a mortality comparison adjusted for age and population size. It does not establish that obesity is always diagnosed only after complications.

The regional government's 2025-2027 programme, launched in September 2025, was planned for 200 children and adolescents. It offers a year of multidisciplinary care, including doctors, dietitians and psychologists. It is delivered by a public paediatric centre in Poznań. It targets children and adolescents with BMI above the 97th percentile; confirm current eligibility and places with the provider.

Adults can access primary care, specialist clinics, NFZ bariatric treatment and private consultations. In 2026, Poznań also announced a funding competition covering adult obesity education and prevention. A competition does not confirm that a comprehensive treatment programme is available to every resident; check current services with the city or provider.